Day: May 3, 2026
Molecule Digest
Pharmaceutical
Sci&Tech
The Nonclinical Studies Lead to the First FDA Approved PROTAC-Veppanu
As a PROTAC (Proteolysis-Targeting Chimera), vepdegestrant represents a novel class of heterobifunctional degraders, and its non-clinical package focused heavily on its unique mechanism and potential for off-target effects. Based on the FDA approval documentation for VEPPANU...